Navigation Links
Calvert Research Licenses Novel Technology to Treat Age Related Macular Degeneration from Tulane University
Date:6/10/2009

Calvert Research, LLC (a unit of Calvert Holdings, Inc.) today announced the execution of a license agreement with Tulane University granting Calvert Research (through its wholly owned subsidiary, Calvert T1, LLC) certain rights to issued patents and patent applications covering a technology platform and novel compounds which have the potential to treat a debilitating eye disease known as Age-related Macular Degeneration (AMD).

Cary, NC (PRWEB) June 9, 2009 -- Calvert Research, LLC (a unit of Calvert Holdings, Inc.) today announced the execution of a license agreement with Tulane University granting Calvert Research (through its wholly owned subsidiary, Calvert T1, LLC) certain rights to issued patents and patent applications covering a technology platform and novel compounds which have the potential to treat a debilitating eye disease known as Age-related Macular Degeneration (AMD). The patented compounds and technology licensed by Calvert T1 were developed in the laboratory of Dr. David H. Coy and his team at the Peptide Research Laboratory at Tulane University.

AMD is a leading cause of blindness in the elderly, affecting millions worldwide and results from the progressive deterioration of the macula, which are the light-sensitive cells of the central retina at the back of the eye. AMD is characterized by two types: a dry (atrophic) and wet (exudative) form. Wet AMD occurs when abnormal blood vessels behind the retina begin to grow under the macula, often leaking blood and fluid that can lead to visual distortions, a decrease or loss of central vision, and eventual blindness.

The preclinical stage compounds licensed by Calvert T1 combine the known anti-proliferative effects of a somatostatin peptide analog with a cytotoxic drug chemically linked to the peptide, resulting in a dual mechanism drug candidate designed to specifically target and kill abnormal blood vessels found in wet AMD patients.

The lead compound from this technology platform has shown activity in an animal model of AMD. Calvert T1 intends to advance it further through additional preclinical studies using its network of preferred pharmaceutical development service providers including Calvert Laboratories, Inc., a leading contract laboratory offering toxicology, pharmacology, immunology, pharmacokinetic and other preclinical services to the biotechnology and pharmaceutical industry.

Russ C. McLauchlan, Chairman and CEO of Calvert Holdings commented: "We are very pleased to enter into this agreement with Dr. Coy and his colleagues at Tulane to further develop this very promising technology for the treatment of wet AMD. This disease is of growing concern to millions of people as our population ages. Calvert has a strong commitment to work with research universities such as Tulane to advance these research efforts." He added: "Calvert T1 is a continuation of investments in a range of technologies over the last several years. Other investments include the following: CureDM (Lankenau Institute) for diabetes, Auburn University for targeted drug delivery, Pinnacle Pharmaceuticals (University of Virginia) for wound healing, and AcSentient II (now owned by Ista Pharmaceuticals, Inc.) for ocular hypertension/open-angle glaucoma.

About Tulane University:
Tulane University is one of the nation's leading educational and research institutions. Founded in 1834 in New Orleans, Tulane has ten schools and colleges offering degrees in architecture, business, law, liberal arts, medicine, public health and tropical medicine, the sciences and engineering, and social work.

About Calvert Research, LLC:
Established in early 2005 to work with early-stage biotechnology companies to advance their lead drug candidates, Calvert Research has further evolved to working closely with Technology Transfer executives of major universities across the country to identify, license, and develop novel compounds and technology platforms in a variety of disease areas.

About Calvert Holdings, Inc.:
Formed in 1996, Calvert Holdings, Inc. (www.calvertholdings.com) is a privately-held company consisting of a diverse portfolio of companies including the following: Calvert Laboratories, Inc.; Calvert Research, LLC; Calvert Creative, LLC; Carolina Securities, Inc. and Calvert Cafe.

Calvert Holdings is a company of people who are passionately engaged in contributing to the future well being of the planet we live on. By analyzing how emerging discoveries and current trends will affect future global needs, we position resources and apply our skills to meet them.

###

Read the full story at http://www.prweb.com/releases/2009/06/prweb2512974.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Calvert Research and Auburn University Announce Joint Venture
2. Calvert Labs Announces the Hiring of Terry Ladd
3. Calvert Research and CureDM Sign Collaborative Agreement
4. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
7. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
8. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
9. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
10. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
11. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Calvert Research Licenses Novel Technology to Treat Age Related Macular Degeneration from Tulane University
(Date:2/11/2016)... BEACH, Florida , February 11, 2016 /PRNewswire/ ... PositiveID Corporation ("PositiveID" or "Company") (OTCQB: PSID), ... diagnostics, announced today that its Thermomedics subsidiary, which ... progress on its growth plan in January 2016, ... products distributors, increasing sequential monthly sales growth, and ...
(Date:2/10/2016)... , Febr. 10, 2016 /PRNewswire/ - BioAmber Inc. (NYSE: ... pleased to announce that Mitsui & Co. Ltd., its ... succinic acid plant, is investing an additional CDN$25 million ... increasing its stake from 30% to 40%.  Mitsui will ... bio-succinic acid produced in Sarnia , ...
(Date:2/10/2016)... , ... February 10, 2016 ... ... today announced that it has joined the Human Vaccines Project, a public-private ... diseases and cancer. , The Human Vaccines Project brings together leading ...
(Date:2/10/2016)... Springfield, MO (PRWEB) , ... February 10, 2016 ... ... company, will attend the International Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter ... of ISPE is expecting to fill more than 100 tables for its annual ...
Breaking Biology Technology:
(Date:1/20/2016)... , Jan. 20, 2016   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... MedNet,s significant achievements are the result of the company,s ... iMedNet eClinical , it,s comprehensive, easy-to-use and ... --> Key MedNet growth achievements in ...
(Date:1/18/2016)... Jan. 18, 2016  Extenua Inc., a pioneering ... the use and access of ubiquitous on-premise and ... with American Cyber.  ... leading transformational C4ISR and Cyber initiatives in support ... latest proven technology solutions," said Steve Visconti ...
(Date:1/13/2016)... ALBANY, New York , January 13, 2016 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2023. According to ... mn in 2014 and is anticipated to reach US$1,625.8 ... from 2015 to 2023. In terms of volume, the ...
Breaking Biology News(10 mins):